AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04431882 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: optic nerve sheath fenestration
Description: A standard medial transconjunctival orbitotomy was performed in all cases under general anesthesia. The medial rectus muscle was disinserted and reflected nasally with 6-0 synthetic polyester suture in typical fashion for eye muscle surgery. A traction suture was then placed through the insertion stump of the medial rectus in a baseball stitch fashion to facilitate abduction of the globe. The pupil was monitored at all times. A custom- made cupped orbital retractor was inserted along the medial scleral wall and used to retract the orbital fat and allow visualization of the optic nerve sheath. Retraction and globe abduction were relaxed if any changes in pupil size were noted. When adequate visualization was achieved, multiple dural sheath fenestrations approximately 3 mm in length. Expulsion of cerebrospinal fluid was invariably observed with the initial incision into the dural sheath.
Study NCT02792959 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Functional Imaging previous the second course
Description: Functional Imaging before and after 1 cycle of chemotherapy treatment, in the previous 4 days before the second course: PET1 and MRI1
Study NCT02792959 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Functional Imaging previous the surgery
Description: Functional Imaging after 4 cycles of chemotherapy treatment, in the 3 weeks after the chemotherapy, before the interval surgery: PET4 and MRI4 The RECIST evaluation will be done, usually, by scanner to 4 courses of chemotherapy before the surgery interval
Study NCT04213352 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Wrist Splint
Description: Neutral position and volar supported wrist orthosis which limits the flexion and deviation while allowing pronation, supination, and extension of the wrist.
Study NCT01015729 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ASA
Description: Tablet, oral, single dose
Study NCT04213352 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Rigid Taping
Description: Rigid taping in the neutral position will be performed to allow pronation, supination, and extension of the wrist while limiting the flexion and deviation.
Study NCT00362479 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DR-1021
Description: 1 tablet daily
Study NCT01211704 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paliperidone Palmitate
Description: NVEGA® SUSTENNA™ or placebo in equivalent ml doses according to the following schedule: Day 1: INVEGA® SUSTENNA™ 234mg vs. placebo injection (equivalent ml); Day 8 (week 1) INVEGA® SUSTENNA™ 156mg vs. placebo injection (equivalent ml); Day 36 (week 5): INVEGA® SUSTENNA™ 117 mg vs. placebo injection (equivalent ml) ( this latter dose could range from 39mg to 156mg according to tolerability and clinical symptoms of bipolar disorder). Treatment with INVEGA® SUSTENNA™ /Placebo will last 5 weeks.
Study NCT01211704 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo in equivalent ml doses to experimental intervention (Paliperidone Palmitate)
Study NCT00973336 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Calcium and vitamin D
Description: 1000mg calcium per day 800 IE vitamin D per day
Study NCT04347343 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Standard Rehabilitation + Neuromuscular Electrical Stimulation and Blood Flow Restriction
Description: Subjects will begin a standardized protocol on post-op day 2. Outpatient visits will be 2x/wk for weeks 0-4 and then 1x/wk for weeks 5-8.~Subjects will utilize NMES on the quadriceps in the home setting 2x/day for the first 3-4 weeks during isometric contractions at their highest tolerated intensity. Total treatment will begin at 10 minutes.~At the end of post-op week 2, subjects will be exposed in clinic to BFR on the surgical limb increasing to 80% limb occlusion pressure over weeks 3-4 as tolerated. Initially, BFR and NMES will be performed simultaneously. BFR will then be progressed using active exercises. After completing a safety checklist, subjects will be issued a home BFR unit for use 2x/week (3x total including clinic visit) at which time NMES will be discontinued. BFR exercise intensity will be progressed as tolerated to maintain 20-30% of 1RM.
Study NCT04013776 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Phosphate supplemented diet
Description: Participants will be asked to follow a 5 day menu of 750 mg of phosphorus daily along with a daily sodium phosphorus supplement of 500 mg
Study NCT01296750 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Early Physiotherapy start
Description: Physiotherapy starting at one day post op
Study NCT01233024 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: Dinner bar fortified with 0g fiber; breakfast bar fortified with 0g dietary fiber.
Study NCT01233024 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Soluble corn fiber
Description: Dinner bar fortified with 12g fiber; breakfast bar fortified with 11g dietary fiber.
Study NCT01233024 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Resistant starch
Description: Dinner bar fortified with 12g fiber; breakfast bar fortified with 11g dietary fiber.
Study NCT01233024 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Fructooligosaccharide
Description: Dinner bar fortified with 12g fiber; breakfast bar fortified with 11g dietary fiber.
Study NCT01233024 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Inulin
Description: Dinner bar fortified with 12g fiber; breakfast bar fortified with 11g dietary fiber.
Study NCT00894699 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sublingual Sufentanil/Triazolam NanoTab™ (ARX-F03)
Description: Single dose of sublingual Sufentanil 15 mcg/Triazolam 200 mcg NanoTab™
Study NCT00894699 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo NanoTab™
Description: Single dose of sublingual placebo NanoTab™
Study NCT01215656 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Lactobacillus fermentum
Study NCT01215656 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Follow on formula without probiotics
Study NCT00495235 — intervention group
Intervention type: BEHAVIORAL
Intervention: Questionnaire
Description: Questionnaire taking about 20 minutes to complete.
Study NCT01284959 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: risperidone
Description: risperidone 3mg, PO, 3 times
Study NCT01284959 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paliperidone ER
Description: paliperidone ER 6mg, PO,3 times
Study NCT01284959 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: lactose PO, 3times
Study NCT01882777 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Household drinking water filters and cookstoves
Description: The intervention consists of providing households with a household-based drinking water filter (Lifestraw® Family version 2.0) and high efficiency cook stoves (Eco Zoom) as well as instructions on how to use them. The intervention is delivered at community level through community health workers (CHWs). Following initial distribution of the products, CHWs visit households fortnightly to reinforce messages about correct and consistent use.
Study NCT01104363 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Snow white plaster 2
Description: Test. Plaster impression not splinted.
Study NCT01104363 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Primopattern LC gel + PVS
Description: Control PVS impression
Study NCT03071380 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Repatoxaban
Description: 1 tablet contains 10 mg rivaroxaban
Study NCT03071380 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Xarelto
Description: 1 tablet contains 10 mg rivaroxaban
Study NCT03380624 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Refresh Optive
Description: Lubricate and hydrating relief of eye dryness investigational lubricant eye drop is based on carboxymethylcellulose
Study NCT03380624 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Refresh Optive MEGA-3
Description: Lubricate and hydrating relief of eye dryness investigational lubricant eye drop is based on carboxymethylcellulose and with flaxseed oil and trehalose
Study NCT04971343 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Access HIV_Canada's requirements_HIV positive
Description: To fit with Canada's requirements:~o HIV positive samples will be equally distributed and tested at leat three (3) testing sites, using 3 lots of reagents.
Study NCT01043848 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: external electric pudendal nerve stimulation
Description: intervention timing: twice daily for 20 minutes during 3 consecutive months.~intervention procedure: electrodes will be placed around the penile shaft (in males) or clips will be directly placed on the clitoris (in females).~intervention device: contic+~stimulation parameters: 10 Hz, 200μs pulse width, 10mA (or less, if too uncomfortable).
Study NCT01063790 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Individualized Education
Description: The intervention consists of written information in the form of a booklet, an individualized face to face education session and two telephone support calls regarding post-discharge pain management, adverse effects of analgesics and common concerns about asking for help with pain.Participants in the intervention group will also receive two telephone support calls. The purpose of the telephone support calls is to readdress the information that patients received in the booklet and to clarify concerns regarding post-operative pain management that were discussed during the individualized education session.
Study NCT01160133 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Systane
Description: Systane Lubricant Eye Drops (1-2 drops in each eye, four times per day)
Study NCT01160133 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Refresh Tears
Description: Refresh Tears Lubricant Eye Drops (1-2 drops in each eye, four times per day)
Study NCT02546583 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Increased Intravenous Bolus Loop Diuretic Dose (Bumetanide or Furosemide)
Description: An increase to 2.5x the Visit 1 dose of loop diuretic (bumetanide or furosemide).
Study NCT02546583 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IV Chlorothiazide
Study NCT04179305 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Oncolo-GIST
Description: Behavioral: Oncolo-GIST Oncolo-GIST is a brief, manualized communication intervention that guides oncologists in gist communication by itemizing 4 key steps in the process of imparting prognostic information.~Topics covered include:~Principles of introducing prognosis in the setting of worsened scan results Coupling communicating realistic prognoses with psychological support (e.g., saying average life-expectancy is months... with emphasizing that the oncology team will always provide care for you) Addressing informational needs and psychological reactions Applying proven techniques for supporting patients who are reluctant to discuss prognosis.~The 4-step guide will include brief video-clips of demonstrating each talking point with a standardized patient, including ideal scenarios, common pitfalls to avoid, and how to respond to patient reactions that are particularly challenging, such as responding to optimism, death anxiety, and reliance on faith.
Study NCT04179305 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Usual Care Arm
Description: Oncologists will provide care in non-specific manner.
Study NCT00401843 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Siltuximab
Description: Siltuximab 6 mg/kg will be administered as intravenous infusion once every 2 weeks during cycle 1 in Part 1. Siltuximab 6 mg/kg will be administered as intravenous infusion once every 2 weeks during 42-day Treatment Phase and 35-day Maintenance Phase in Part 2.
Study NCT00401843 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: Bortezomib 1.3 mg/m\^2 will be administered as intravenous bolus once every 2 weeks during cycle 1 in Part 1. Bortezomib 1.3 mg/m\^2 will be administered as intravenous bolus on Days 1, 4, 8, 11, followed by a 10-day rest period; and on Days 22, 25, 29, and 32 followed by a 10-day rest period during 42-day treatment phase in Part 2. Bortezomib 1.3 mg/m2 will be administered as intravenous bolus on Days 1, 8, 15, 22 followed by a 13-day rest period (cycle Days 23 to 35) during 35-day Maintenance Phase in Part 2.
Study NCT00401843 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching placebo will be administered as intravenous infusion once every 2 weeks during 42-day treatment phase and 35-day maintenance phase in Part 2.
Study NCT00401843 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Dexamethasone tablet will be administered in this study at the first occurrence of documented disease progression or if bortezomib was discontinued due to intolerable toxicity. Dexamethasone 40 mg/day will be administered on days 1-4, 9-12, and 17-20 for four 28-day cycles then 40 mg/day for Days 1-4 for all subsequent cycles in treatment phase and maintenance phase of Part 2.
Study NCT03338868 — intervention group
Intervention type: OTHER
Intervention: Physical activity level
Description: assessed by the International Physical Activity Questionnaire-7
Study NCT01214473 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Synbiotics
Description: Lactobacillus plantarum with fructo-oligosaccharide
Study NCT01214473 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Maltodextrin
Description: Only maltodextrin as placebo
Study NCT00005739 — intervention group
Intervention type: BEHAVIORAL
Intervention: Community-based directly observed therapy (DOT)
Description: A community-based intervention conducted by trained graduates of a TB directly observed therapy (DOT) program (peer workers)
Study NCT00005739 — intervention group
Intervention type: BEHAVIORAL
Intervention: Clinic directly observed therapy (DOT)
Description: A traditional self-administered preventive treatment
Study NCT03364231 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Umbralisib
Description: Oral Daily Dose
Study NCT04971343 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Access HIV_Canada's requirements_P24 Positive
Description: To fit with Canada's requirements:~* HIV positive samples will be equally distributed and tested at leat three (3) testing sites, using 3 lots of reagents.~* Collection and testing of maximum 210 additional HIV-1 Ag positive sample beyond the 50 required by CTS
Study NCT02985957 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Specified dose on specified days
Study NCT02985957 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Specified dose on specified days
Study NCT02985957 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabazitaxel
Description: Specified dose on specified days
Study NCT02985957 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Specified dose on specified days
Study NCT03416946 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Visionaire
Description: Custom cutting block using MRI to create patient specific instrumentations
Study NCT03416946 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Traditional
Description: Traditional cutting method
Study NCT03584178 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Budesonide via MAD device
Description: Delivery through Mucosal Atomization Device
Study NCT03584178 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Budesonide via intranasals Saline Irrigation
Description: delivery via nasal irrigation bottle
Study NCT04017078 — intervention group
Intervention type: OTHER
Intervention: diagnosis of carotid artery calcification on digital panoramic radiograph
Description: Suspected carotid arty calcifications findings were defined as one or more radiopaque mass adjacent to the cervical vertebrae at or below the intervertebral space between C3 and C4 on the DPR.
Study NCT03509558 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcutaneous spinal stimulation
Description: Non-invasive electrical stimulation of spinal cord over the skin combined with physical therapy to improve walking and standing functions
Study NCT03509558 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Physical Therapy
Description: physical therapy to improve walking and standing functions
Study NCT03367221 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NAVA ventilation
Description: Assisted Ventilation Mode, synchronized, through EAdi catheter, with patient's inspiratory effort and proportional to respiratory drive
Study NCT01780077 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: RXI-109
Description: Multiple intradermal injections of RXI-109 at incision sites
Study NCT01780077 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RXI-109
Description: Multiple intradermal injections of RXI-109 at incision sites
Study NCT01780077 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Multiple intradermal injections of placebo at incision sites
Study NCT01780077 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Multiple intradermal injections of placebo at incision sites
Study NCT00870883 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine and deferoxamine
Description: N-acetylcysteine bolus dose of 50mg/kg/4h, by a manutention of 100mg/kg/day during 2 days and deferoxamine single dose of 1g administered 15mg/kg/h.
Study NCT04457635 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Psychotherapy
Study NCT04457635 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Psychotherapy
Study NCT00560456 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Chronic sleep restriction and driving simulator
Description: * One night of normal sleep~* Driving simulator~* Night 1: night of total sleep deprivation~* Night 2: night of sleep recovery~* Night 1 to 5: nights of sleep restriction~* Driving simulator after night 1 to 5~* Night 6: night of sleep recovery~* Driving simulator
Study NCT00560456 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Chronic sleep restriction and driving simulator
Description: * One night of normal sleep~* Driving simulator~* Night 1: night of total sleep deprivation~* Night 2: night of sleep recovery~* Night 1 to 5: nights of sleep restriction~* Driving simulator after night 1 to 5~* Night 6: night of sleep recovery~* Driving simulator
Study NCT02425371 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Screening and treatment of comorbidities
Description: Screening and treatment of comorbidities
Study NCT02425371 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Comparator
Description: No screening of comorbidities
Study NCT01744574 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo - subjects will take 200 mg twice daily orally (approximately 8am and 8pm) for twelve weeks starting seven days prior to the assigned quit date.
Study NCT01744574 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Progesterone
Description: The progesterone will be given in the form of an active micronized natural progesterone (Prometrium). All subjects will take 200 mg twice daily orally (approximately 8am and 8pm) for twelve weeks starting seven days prior to the assigned quit date.
Study NCT01744574 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Smoking Cessation Behavioral Counseling
Description: Subjects will receive weekly smoking cessation behavioral counseling.
Study NCT01744574 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Smoking Cessation Behavioral Counseling
Description: Subjects will receive weekly smoking cessation behavioral counseling.
Study NCT03226483 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Intraoperative Radiotherapy
Description: Intraoperative Radiotherapy is performed with a mobile radiation device emitting soft energy x-rays in a spherical way. Different size applicators are available to cover the resection cavity after the tightest fit rule.
Study NCT03652272 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: EMC2
Description: 1. Prescribers will receive a 'Best Practices Alert' which recommends patient counseling on medication use and provides an overview of key medication risks~2. Patients will receive a Medication Guide + Summary with their After Visit Summary~3. Patients will be asked to complete a brief questionnaire on medication use via the patient portal post visit (at both 1 week and 1 month post visit for this phase of the study)~4. Portal assessment results and feedback will be provided to the clinic via an inbox message. Clinic staff will respond to any identified problems according to their own clinical care protocols.
Study NCT03201367 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rivaroxaban
Description: Rivaroxaban 10 mg/12 hour
Study NCT03201367 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: symptomatic therapy for ascites, abdominal pain
Study NCT03634878 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: perineal ultrasound
Description: Ultrasound measurement of the size and position of the prostheses.